All In Biotech

Drug Trial Radar · NCT04280718

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

229

Actual

Start

Sep 18, 2020

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Lead sponsor
argenxargenx (ARGX)
Sponsor type
Industry
First posted
Feb 21, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the open-label extension study of phase II ARGX-113-1802 to evaluate the long-term safety and efficacy of the subcutaneous formulation of efgartigimod in adults with CIDP. Patients already stabilized on efgartigimod PH20 SC will also have the opportunity to participate in a sub study to explore less frequent dosing of efgartigimod PH20 SC.

Conditions

  • Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Interventions

  • Efgartigimod PH20 SCBiological

    Subcutaneous administration of efgartigimod

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events and serious adverse eventsTime frame: Up to 48 weeks per cycle (each cycle is 48 weeks) until the end of the study

Locations

147 sites in 24 countries. Site status is shown where the registry gives one.

  • Investigator site 0010065

    Birmingham, Alabama

  • Investigator site 0010013

    Phoenix, Arizona

  • Investigator site 0010055

    Scottsdale, Arizona

  • Investigator site 0010032

    Carlsbad, California

  • Investigator site 10190

    Pomona, California

  • Investigator site 0010160

    Rancho Mirage, California

  • Investigator site 0010071

    San Francisco, California

  • Investigator site 0010057

    Centennial, Colorado

  • Investigator site 0010072

    Boca Raton, Florida

  • Investigator site 0010144

    Coral Springs, Florida

  • Investigator site 0010023

    Jacksonville, Florida

  • Investigator site 0010068

    Maitland, Florida

  • Investigator site 0010059

    Miami, Florida

  • Investigator site 0010006

    Tampa, Florida

  • Investigator site 0010011

    Iowa City, Iowa

  • Investigator site 0010015

    Fairway, Kansas

  • Investigator site 10147

    Lexington, Kentucky

  • Investigator site 10168

    New York, New York

  • Investigator site 0010003

    Chapel Hill, North Carolina

  • Investigator site 0010064

    Columbus, Ohio

  • Investigator site 0010007

    Philadelphia, Pennsylvania

  • Investigator site 0010047

    Philadelphia, Pennsylvania

  • Investigator Site 0010066

    Austin, Texas

  • Investigator site 0010009

    San Antonio, Texas

  • Investigator site 0010061

    Richmond, Virginia

  • Investigator site 0430007

    Innsbruck, Austria

  • Investigator site 0430008

    Linz, Austria

  • Investigator site 0430005

    Vienna, Austria

  • Investigator site 0320016

    Edegem, Belgium

  • Investigator site 0320009

    Leuven, Belgium

  • Investigator site 320024

    Liège, Belgium

  • Investigator site 320022

    Woluwe-Saint-Lambert, Belgium

  • Investigator site 3590007

    Pleven, Bulgaria

  • Investigator site 3590005

    Sofia, Bulgaria

  • Investigator site 3590008

    Sofia, Bulgaria

  • Investigator site 3590006

    Sofia, Bulgaria

  • Investigator site 0860033

    Beijing, China

  • Investigator site 860041

    Changsha, China

  • Investigator site 0860036

    Chengdu, China

  • Investigator site 860049

    Chifeng, China

Showing 40 of 147 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.